Maharashtra’s Food and Drugs Administration has publicly warned three high-profile Bollywood actors that they could face financial penalties connected to an advertisement for an elaichi (cardamom) product. The statement, made by an FDA official and reported in Indian media, says legal action may follow while the agency examines the claim that the ad breaches advertising rules.
What the FDA said and what is reported
An official from the Maharashtra Food and Drugs Administration, identified in media reports as Tukaram Mundhe, said the agency is examining an advertisement that features actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff. According to those reports, Mundhe told reporters the stars “could be” liable for a penalty of up to ₹10 lakh (one million rupees) if the ad is found to contravene regulations. The Times of India carried the original account of his remarks.
The precise nature of the alleged breach and the product’s packaging or claims were not detailed in the report. The FDA official’s comments, as reported, indicate the possibility of legal action; they do not constitute a final finding. It is unconfirmed at this stage whether any notice has been formally issued to the actors, their production companies or the advertiser, or whether the investigation has progressed to an enforcement step.
Why regulators are watching advertisements closely
In India, advertising for certain categories of products is subject to strict rules. Tobacco products, many chewable tobacco preparations and some pan masala products face advertising restrictions under national law. Authorities also scrutinise so-called “surrogate advertising,” where a brand promotes a non-regulated product bearing the same name or imagery as a restricted product, in order to circumvent advertising bans.
State-level food and drug administrations, like Maharashtra’s FDA, have powers to inspect consumer products, monitor compliance with labelling and advertising rules, and initiate enforcement action if they find breaches. A high-profile advertisement involving major celebrity endorsers naturally attracts attention because of its visibility and potential influence on consumer behaviour.
The FDA’s public comment reflects that enforcement bodies are monitoring celebrity endorsements and brand campaigns for possible regulatory violations. Whether the contested ad falls into the categories that attract penalties depends on the product’s classification, the content of the ad and the findings of any formal investigation.
What this means for Bollywood, brands and audiences abroad
Bollywood stars frequently serve as national and international brand ambassadors. Their endorsement deals and promotional appearances help sell films to the Indian diaspora and wider global audiences. When regulators raise concerns about an advertisement, it can have multiple effects: potential fines for the advertiser, reputational risk for the celebrity, and caution among marketers planning future campaigns.
For readers outside India, the episode illustrates the regulatory environment that surrounds media promotion in one of the world’s largest film industries. Advertising rules in India sometimes differ sharply from those in other markets: some categories are banned or tightly regulated and surrogate advertising is actively policed. That can shape the strategies used by studios and sponsors when they launch films or consumer products aimed at audiences at home and abroad.
If the FDA proceeds with enforcement, the outcome could set a precedent in how strictly authorities enforce advertising restrictions involving film personalities. If no formal action follows, the public warning may still influence brands and talent managers to review compliance practices.
What remains unconfirmed and what to watch next
At this point, several facts remain unconfirmed in public reports: whether a formal charge or notice has been served to the actors or the advertiser; the specific legal provision alleged to have been violated; and the advertiser’s response or defence. Neither the actors’ representatives nor the advertiser’s official statements were included in the media report cited here.
Readers should watch for updates from the Maharashtra FDA, statements from the actors’ teams or the advertiser, and follow-up reporting that may publish the text of any notice or legal filing. If the matter proceeds to court or an adjudicatory process, official documents will provide the clearest account of the alleged infringement and any penalty imposed.
This article was produced with AI assistance and checked before publication. Editorial policy
